{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-057018","form_type":"8-K","ticker":"COYA","cik":"0001835022","company_name":"Coya Therapeutics, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.585714+00:00","generated_at":"2026-06-02T06:58:31.069005+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Coya Therapeutics Reports Q1 2024 Net Loss of $5.1M and Cash of $36.0M, Advances Pipeline","bullets":["Net loss was $5.1M for Q1 2024 vs $2.7M in Q1 2023; R&D expenses rose to $3.1M from $1.2M.","Cash and cash equivalents totaled $36.0M as of March 31, 2024, providing runway into 2026.","IND filing for COYA 302 in ALS expected in 2Q24, with Ph. 2 trial initiation thereafter.","Pipeline expanded to include Frontotemporal Dementia, Parkinson’s, and Alzheimer’s diseases.","Licensed next-generation immune modulatory biologics from University of Nebraska Medical Center in Feb 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-057018","json":"https://secwatch.observer/filing/0000950170-24-057018.json","markdown":"https://secwatch.observer/filing/0000950170-24-057018.md","text":"https://secwatch.observer/filing/0000950170-24-057018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835022/000095017024057018/0000950170-24-057018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835022/000095017024057018/coya-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:58:31.069005+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0daf90a741ec3540ee28190e0f288cabf200345d","claim":"Coya Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income Net loss was $5.1 million for the three months ended March 31, 2024.","evidence_excerpt":"Net loss was $5.1 million for the three months ended March 31, 2024, compared to net loss of $2.7 million for the three months ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835022/000095017024057018/0000950170-24-057018-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss was $5.1 million for the three months ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}